Novel antagonists of growth hormone-releasing hormone inhibit growth and vascularization of human experimental ovarian cancers

Cancer

Volumn 118, Issue 3, 2012, Pages 670-680

  Klukovits, Anna ^a,b   Schally, Andrew V ^a,b   Szalontay, Luca ^a   Vidaurre, Irving ^a   Papadia, Andrea ^b,c   Zarandi, Marta ^a,b   Varga, Jozsef L ^a,b   Block, Norman L ^a,b,c   Halmos, Gabor ^a,b,d  

^a VETERANS AFFAIRS MEDICAL CENTER   (United States)

^b UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF MIAMI   (United States)

^d UNIVERSITY OF DEBRECEN   (Hungary)

Author keywords

growth hormone releasing hormone; ovarian cancer; vascular endothelial growth factor; vascularization

Indexed keywords

GROWTH HORMONE RELEASING FACTOR; GROWTH HORMONE RELEASING FACTOR RECEPTOR; HORMONE RECEPTOR BLOCKING AGENT; MIA 313; MIA 602; MIA 604; MIA 610; UNCLASSIFIED DRUG; VASCULOTROPIN; VASCULOTROPIN RECEPTOR;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIANGIOGENIC ACTIVITY; ARTICLE; CANCER CELL CULTURE; CANCER INHIBITION; CELL STRAIN OVCAR 3; CELL STRAIN SKOV 3; CELL VIABILITY; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; EXPERIMENTAL NEOPLASM; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; ILEUM; IN VITRO STUDY; IN VIVO STUDY; MOUSE; NONHUMAN; NUDE MOUSE; OVARY ADENOCARCINOMA; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN SECRETION; PROTEIN SYNTHESIS INHIBITION; TUMOR VASCULARIZATION; TUMOR XENOGRAFT; WESTERN BLOTTING;

ANIMALS; BLOTTING, WESTERN; CELL PROLIFERATION; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; GROWTH HORMONE-RELEASING HORMONE; HUMANS; MICE; MICE, NUDE; NEOVASCULARIZATION, PATHOLOGIC; OVARIAN NEOPLASMS; SERMORELIN; TUMOR CELLS, CULTURED; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 83455199632     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.26291     Document Type: Article

References (32)

1. Galaal K, Naik R, Bristow RE, Patel A, Bryant A, Dickinson HO,. Cytoreductive surgery plus chemotherapy versus chemotherapy alone for recurrent epithelial ovarian cancer. Cochrane Database Syst Rev. 2010; 6: CD007822.
2. Scholz HS, Tasdemir H, Hunlich T, Turnwald W, Both A, Egger H,. Multivisceral cytoreductive surgery in FIGO stages IIIC and IV epithelial ovarian cancer: results and 5-year follow-up. Gynecol Oncol. 2007; 106: 591-595.
3. du Bois A, Luck HJ, Meier W, et al. A randomized clinical trial of cisplatin/paclitaxel versus carboplatin/paclitaxel as first-line treatment of ovarian cancer. J Natl Cancer Inst. 2003; 95: 1320-1329.
4. Thigpen T, Stuart G, du Bois A, et al. Clinical trials in ovarian carcinoma: requirements for standard approaches and regimens. Ann Oncol. 2005; 16: viii13-viii19.
5. Heintz AP, Odicino F, Maisonneuve P, et al. Carcinoma of the ovary. FIGO 6th Annual Report on the Results of Treatment in Gynecological Cancer. Int J Gynecol Obstet. 2006; 95: S161-S192.
6. Coleman RL, Broaddus RR, Bodurka DC, et al. Phase II trial of imatinib mesylate in patients with recurrent platinum and taxane-resistant epithelial ovarian and primary peritoneal cancers. Gynecol Oncol. 2006; 101: 126-131.
7. Schilder RJ, Sill MW, Chen X, et al. Phase II study of gefitinib in patients with relapsed or persistent ovarian or primary peritoneal carcinoma and evaluation of epidermal growth factor receptor mutations and immunocytochemical expression: a Gynecologic Oncology Group Study. Clin Cancer Res. 2005; 11: 5539-5548.
8. Bookman MA, Darcy KM, Clarke-Pearson D, Boothby RA, Horowitz IR,. Evaluation of monoclonal humanized anti-HER2 antibody, trastuzumab, in patients with recurrent or refractory ovarian or primary peritoneal carcinoma with overexpression of HER2: a phase II trial of the Gynecologic Oncology Group. J Clin Oncol. 2003; 21: 283-290.
9. Spannuth WA, Sood AK, Coleman RL,. Angiogenesis as a strategic target for ovarian cancer therapy. Nat Clin Pract Oncol. 2008; 5: 194-204.
10. Han ES, Monk BJ,. Bevacizumab in the treatment of ovarian cancer. Expert Rev Anticancer Ther. 2007; 7: 1339-1345.
11. Wright JD, Hagemann A, Rader JS, et al. Bevacizumab combination therapy in recurrent, platinum-refractory, epithelial ovarian carcinoma: a retrospective analysis. Cancer. 2006; 107: 83-89.
12. Cannistra SA, Matulonis UA, Penson RT, et al. Phase II study of bevacizumab in patients with platinum-resistant ovarian cancer or peritoneal serous cancer. J Clin Oncol. 2007; 25: 5180-5186.
13. Hapani S, Chu D, Wu S,. Risk of gastrointestinal perforation in patients with cancer treated with bevacizumab: a meta-analysis. Lancet Oncol. 2009; 10: 559-568.
14. Schally AV, Varga JL, Engel JB,. Antagonists of growth-hormone-releasing hormone: an emerging new therapy for cancer. Nat Clin Pract Endocrinol Metab. 2008; 4: 33-43.
15. Kanashiro CA, Schally AV, Zarandi M, Hammann BD, Varga JL,. Alterations of EGFR/HER, angiogenesis and apoptosis pathways after therapy with antagonists of growth hormone releasing hormone and bombesin in non-small cell lung cancer. Int J Oncol. 2007; 30: 1019-1028.
16. Pozsgai E, Schally AV, Zarandi M, Varga JL, Vidaurre I, Bellyei S,. The effect of GHRH antagonists on human glioblastomas and their mechanism of action. Int J Cancer. 2010; 127: 2313-2322.
17. Bellyei S, Schally AV, Zarandi M, Varga JL, Vidaurre I, Pozsgai E,. GHRH antagonists reduce the invasive and metastatic potential of human cancer cell lines in vitro. Cancer Lett. 2010; 293: 31-40.
18. Zarandi M, Kovacs M, Horvath JE, et al. Synthesis and in vitro evaluation of new potent antagonists of growth hormone-releasing hormone (GH-RH). Peptides. 1997; 18: 423-430.
19. Varga JL, Schally AV, Csernus VJ, et al. Synthesis and biological evaluation of antagonists of growth hormone-releasing hormone with high and protracted in vivo activities. Proc Natl Acad Sci U S A. 1999; 96: 692-697.
20. Tomayko MM, Reynolds CP,. Determination of subcutaneous tumor size in athymic (nude) mice. Cancer Chemother Pharmacol. 1989; 3: 148-154.
21. Halmos G, Schally AV, Czompoly T, Krupa M, Varga JL, Rekasi Z,. Expression of growth hormone-releasing hormone and its receptor splice variants in human prostate cancer. J Clin Endocrinol Metab. 2002; 87: 4707-4714.
22. Fang J, Zhou Q, Liu LZ, et al. Apigenin inhibits tumor angiogenesis through decreasing HIF-1alpha and VEGF expression. Carcinogenesis. 2007; 28: 858-864.
23. Havt A, Schally AV, Halmos G, et al. The expression of the pituitary growth hormone-releasing hormone receptor and its splice variants in normal and neoplastic human tissues. Proc Natl Acad Sci U S A. 2005; 102: 17424-17429.
24. Chatzistamou I, Schally AV, Varga JL, et al. Antagonists of growth hormone-releasing hormone and somatostatin analog RC-160 inhibit the growth of the OV-1063 human epithelial ovarian cancer cell line xenografted into nude mice. J Clin Endocrinol Metab. 2001; 86: 2144-2152.
25. Chatzistamou I, Schally AV, Varga JL, Groot K, Armatis P, Bajo AM,. Inhibition of growth and reduction in tumorigenicity of UCI-107 ovarian cancer by antagonists of growth hormone-releasing hormone and vasoactive intestinal peptide. J Cancer Res Clin Oncol. 2001; 127: 645-652.
26. Kahan Z, Arencibia JM, Csernus VJ, et al. Expression of growth hormone-releasing hormone (GHRH) messenger ribonucleic acid and the presence of biologically active GHRH in human breast, endometrial, and ovarian cancers. J Clin Endocrinol Metab. 1999; 84: 582-589.
27. Heinrich E, Schally AV, Buchholz S, et al. Dose-dependent growth inhibition in vivo of PC-3 prostate cancer with a reduction in tumoral growth factors after therapy with GHRH antagonist MZ-J-7-138. Prostate. 2008; 68: 1763-1772.
28. Rekasi Z, Czompoly T, Schally AV, Halmos G,. Isolation and sequencing of cDNAs for splice variants of growth hormone-releasing hormone receptors from human cancers. Proc Natl Acad Sci U S A. 2000; 97: 10561-10566.
29. Randall LM, Monk BJ,. Bevacizumab toxicities and their management in ovarian cancer. Gynecol Oncol. 2010; 117: 497-504.
30. Hagedorn A, Germann PG, Junker-Walker U, et al. Immunohistochemical study about the Flt-1/VEGFR1 expression in the gastrointestinal tract of mouse, rat, dog, swine and monkey. Exp Toxicol Pathol. 2005; 57: 149-159.
31. Giatromanolaki A, Sivridis E, Maltezos E, et al. Hypoxia inducible factor 1alpha and 2alpha overexpression in inflammatory bowel disease. J Clin Pathol. 2003; 56: 209-213.
32. Buchholz S, Schally AV, Engel JB, et al. Potentiation of mammary cancer inhibition by combination of antagonists of growth hormone-releasing hormone with docetaxel. Proc Natl Acad Sci U S A. 2007; 104: 1943-1946.